These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16818615)

  • 21. Telomere length in peripheral blood cells of germline TP53 mutation carriers is shorter than that of normal individuals of corresponding age.
    Trkova M; Prochazkova K; Krutilkova V; Sumerauer D; Sedlacek Z
    Cancer; 2007 Aug; 110(3):694-702. PubMed ID: 17567834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alternative lengthening of telomeres in the human adrenocortical carcinoma cell line H295R.
    Fujiwara M; Kamma H; Wu W; Yano Y; Homma S; Satoh H
    Int J Oncol; 2006 Aug; 29(2):445-51. PubMed ID: 16820888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors.
    Mangerel J; Price A; Castelo-Branco P; Brzezinski J; Buczkowicz P; Rakopoulos P; Merino D; Baskin B; Wasserman J; Mistry M; Barszczyk M; Picard D; Mack S; Remke M; Starkman H; Elizabeth C; Zhang C; Alon N; Lees J; Andrulis IL; Wunder JS; Jabado N; Johnston DL; Rutka JT; Dirks PB; Bouffet E; Taylor MD; Huang A; Malkin D; Hawkins C; Tabori U
    Acta Neuropathol; 2014 Dec; 128(6):853-62. PubMed ID: 25315281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alternative lengthening of telomeres (ALT) and chromatin: is there a connection?
    Nittis T; Guittat L; Stewart SA
    Biochimie; 2008 Jan; 90(1):5-12. PubMed ID: 17935854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme.
    Hakin-Smith V; Jellinek DA; Levy D; Carroll T; Teo M; Timperley WR; McKay MJ; Reddel RR; Royds JA
    Lancet; 2003 Mar; 361(9360):836-8. PubMed ID: 12642053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Telomere length maintenance--an ALTernative mechanism.
    Royle NJ; Foxon J; Jeyapalan JN; Mendez-Bermudez A; Novo CL; Williams J; Cotton VE
    Cytogenet Genome Res; 2008; 122(3-4):281-91. PubMed ID: 19188697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pilocytic astrocytomas have telomere-associated promyelocytic leukemia bodies without alternatively lengthened telomeres.
    Slatter T; Gifford-Garner J; Wiles A; Tan X; Chen YJ; MacFarlane M; Sullivan M; Royds J; Hung N
    Am J Pathol; 2010 Dec; 177(6):2694-700. PubMed ID: 21037079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival.
    McDonald KL; McDonnell J; Muntoni A; Henson JD; Hegi ME; von Deimling A; Wheeler HR; Cook RJ; Biggs MT; Little NS; Robinson BG; Reddel RR; Royds JA
    J Neuropathol Exp Neurol; 2010 Jul; 69(7):729-36. PubMed ID: 20535033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Telomere length is a prognostic factor in neuroblastoma.
    Ohali A; Avigad S; Ash S; Goshen Y; Luria D; Feinmesser M; Zaizov R; Yaniv I
    Cancer; 2006 Sep; 107(6):1391-9. PubMed ID: 16917952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Whole-genome profiling in liposarcomas reveals genetic alterations common to specific telomere maintenance mechanisms.
    Johnson JE; Gettings EJ; Schwalm J; Pei J; Testa JR; Litwin S; von Mehren M; Broccoli D
    Cancer Res; 2007 Oct; 67(19):9221-8. PubMed ID: 17909028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of mutated TP53 on cDNA (but not on DNA template) in pleomorphic xanthoastrocytoma with positive TP53 immunohistochemistry.
    Zakrzewska M; Szybka M; Biernat W; Papierz T; Rieske P; Liberski PP; Zakrzewski K
    Cancer Genet Cytogenet; 2009 Sep; 193(2):93-7. PubMed ID: 19665069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of survival-related genes of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma multiforme.
    Ruano Y; Mollejo M; Camacho FI; Rodríguez de Lope A; Fiaño C; Ribalta T; Martínez P; Hernández-Moneo JL; Meléndez B
    Cancer; 2008 Apr; 112(7):1575-84. PubMed ID: 18260157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ALT-associated promyelocytic leukaemia body (APB) detection as a reproducible tool to assess alternative lengthening of telomere stability in liposarcomas.
    Venturini L; Erdas R; Costa A; Gronchi A; Pilotti S; Zaffaroni N; Daidone M
    J Pathol; 2008 Mar; 214(4):410-4. PubMed ID: 18085522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The telomere maintenance mechanism spectrum and its dynamics in gliomas.
    Kim S; Chowdhury T; Yu HJ; Kahng JY; Lee CE; Choi SA; Kim KM; Kang H; Lee JH; Lee ST; Won JK; Kim KH; Kim MS; Lee JY; Kim JW; Kim YH; Kim TM; Choi SH; Phi JH; Shin YK; Ku JL; Lee S; Yun H; Lee H; Kim D; Kim K; Hur JK; Park SH; Kim SK; Park CK
    Genome Med; 2022 Aug; 14(1):88. PubMed ID: 35953846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oropharyngeal squamous cell carcinoma treated with radiotherapy or radiochemotherapy: prognostic role of TP53 and HPV status.
    Fallai C; Perrone F; Licitra L; Pilotti S; Locati L; Bossi P; Orlandi E; Palazzi M; Olmi P
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1053-9. PubMed ID: 19577857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Telomere maintenance in sarcomas.
    Johnson JE; Broccoli D
    Curr Opin Oncol; 2007 Jul; 19(4):377-82. PubMed ID: 17545803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area.
    Eachkoti R; Hussain I; Afroze D; Aejazaziz S; Jan M; Shah ZA; Das BC; Siddiqi MA
    Cancer Lett; 2007 Apr; 248(2):308-20. PubMed ID: 16996204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Telomere uncapping and alternative lengthening of telomeres.
    Cesare AJ; Reddel RR
    Mech Ageing Dev; 2008; 129(1-2):99-108. PubMed ID: 18215414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting ALT: the role of alternative lengthening of telomeres in pathogenesis and prevention of cancer.
    Bollmann FM
    Cancer Treat Rev; 2007 Dec; 33(8):704-9. PubMed ID: 17933469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.
    Rossi D; Cerri M; Deambrogi C; Sozzi E; Cresta S; Rasi S; De Paoli L; Spina V; Gattei V; Capello D; Forconi F; Lauria F; Gaidano G
    Clin Cancer Res; 2009 Feb; 15(3):995-1004. PubMed ID: 19188171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.